SCHEMBL1355941

SCHEMBL1355941

COc1ccc(Nc2ncc3cnn(-c4ccc(OC)cc4C)c3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK4 Q9P2K8 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ MAPT P10636 3/20 0.54
▸ PIP4K2A P48426 1/20 0.54
▸ CDK4 P11802 1/20 0.48
▸ CCND1 P24385 1/20 0.48
▸ CCND2 P30279 1/20 0.48
▸ CCND3 P30281 1/20 0.48
▸ CRHR1 P34998 3/20 0.46
▸ TBK1 Q9UHD2 2/20 0.46
▸ AURKA O14965 2/20 0.45
▸ SYK P43405 1/20 0.45
▸ FGFR1 P11362 2/20 0.45
▸ EGFR P00533 2/20 0.45
▸ SRC P12931 1/20 0.45
▸ FLT3 P36888 3/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ PAK4 O96013 1/20 0.43
▸ ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355905 0.92 EIF2AK4 (0.47) EIF2AK4LMNAMAPTPIP4K2ACDK4
SCHEMBL1356733 0.91 CHRNA7 (0.47) EIF2AK4LMNAMAPTPIP4K2ACDK4
SCHEMBL1356282 0.90 FLT3 (0.52) EIF2AK4LMNAMAPTPIP4K2ACDK4
SCHEMBL1356000 0.88 AURKA (0.44) EIF2AK4LMNAMAPTPIP4K2ACDK4
SCHEMBL1355282 0.88 KDR (0.46) EIF2AK4LMNAMAPTPIP4K2ACDK4
SCHEMBL1355810 0.87 CDK4 (0.60) CDK4CCND1CCND2CCND3TBK1
SCHEMBL1355729 0.84 FGFR4 (0.50) EIF2AK4MAPTCDK4AURKASYK
SCHEMBL1356019 0.78 EIF2AK4 (0.61) EIF2AK4MAPTPIP4K2ACDK4CCND1
SCHEMBL1356007 0.78 EIF2AK4 (0.67) EIF2AK4CDK4CCND1CCND2CCND3
SCHEMBL1356186 0.78 EIF2AK4 (0.67) EIF2AK4CDK4CCND1CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 — — US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 — — US claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 — — US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885LMNA 1636/4885MAPT 733/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885LMNA 1636/4885MAPT 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback